David J. Hackam
13Patents
4h-index
7Co-inventors
49Inventor score
Filing activity: Apr 17, 2008 → Apr 21, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8188058B2 | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders | Human Necessities | 48 | Active |
| US8518905B2 | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment of prevention of toll-like receptor-4-associated disorders | Human Necessities | 14 | Active |
| US8518903B2 | Use of toll-like receptor-9 agonists | Chemistry; Metallurgy | 9 | Active |
| US9072760B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | Human Necessities | 8 | Active |
| US9562066B2 | Oral therapy of necrotizing enterocolitis | Human Necessities | 2 | Active |
| US9532999B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | Human Necessities | 2 | Active |
| US9549980B2 | Methods of treating necrotizing enterocolitis by administering nuclear oligomerization domain-2 agonists,TLR9 agonists and TLR4 antagonists | Chemistry; Metallurgy | 2 | Active |
| US11458141B2 | Aryl hydrocarbon receptor (AhR) agonists for the prevention and treatment of inflammatory disorders | Human Necessities | 0 | Active |
| US11413299B2 | Compositions and methods for treatment of inflammatory disorders | Human Necessities | 0 | Active |
| US10172848B2 | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease | Human Necessities | 0 | Active |
| US10300083B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | Human Necessities | 0 | Active |
| US10668092B2 | Compositions and methods for treatment of inflammatory disorders | Human Necessities | 0 | Active |
| US10933077B2 | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.